Treatment of Overactive Bladder with Once-daily Extended-release Tolterodine or Oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET)

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the stan-dardisation sub-committee of The International Continence Society. Neurourol Urodyn 2002;21:167–78
   PubMed Web of Science ®Google Scholar
• Stewart W, Herzog R, Wein A, et al. Prevalence of overactive bladder in the US: results from the NOBLE Program. Poster presented at the 2nd International Consultation on Incontinence, Paris, France 2001
   Google Scholar
• Bo K, Berghmans LC. Nonpharmacologic treatments for over-active bladder-pelvic floor exercises. Urology 2000;55 (5A Suppl):7–11
   PubMed Web of Science ®Google Scholar
• Payne CK. Behavioral therapy for overactive bladder. Urology 2000;55 (5A Suppl):3–6
   PubMed Web of Science ®Google Scholar
• Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55 (5A Suppl):33–46
   PubMed Web of Science ®Google Scholar
• Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161:1809–12
   Google Scholar
• van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414–21
   PubMed Web of Science ®Google Scholar
• Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801–10
   PubMedGoogle Scholar
• Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283–9
   PubMedGoogle Scholar
• Coyne K, Matza LS. Validation of the perception of bladder condition measure in overactive bladder. Value Health 2002, in press (Abstr)
   Google Scholar
• Laporte JR. From clinical trials to usual practice: efficacy and effectiveness in clinical pharmacology. Methods Find Exp Clin Pharmacol 1999;21(Suppl B):17
   Google Scholar
• Lelorier J. The science of health technology assessment – clinical effectiveness of therapeutic interventions. Can J Clin Pharmacol 2001;8(Suppl A):21–31A
   Google Scholar
• Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991;145:813–16
   PubMed Web of Science ®Google Scholar
• Appell R. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(Suppl 6A):90–6
   Google Scholar
• Nilvebrant L. Tolterodine – a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195–207
   PubMed Web of Science ®Google Scholar
• Nilvebrant L. Clinical experiences with tolterodine. Life Sci 2001;68 (22–23):2549–56
   Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with destrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988–93
   PubMedGoogle Scholar
• Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551–60
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P. Long-term (12-months) efficacy and tolerability of tolterodine once daily in the treatment of overactive bladder. ICS 2001. Neurourol Urodyn 2001;20:401–2 (Abstr)
   Google Scholar
• Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000;95:718–21
   PubMed Web of Science ®Google Scholar
• Appell RA, Diokno A, Antoei J, Labasky RF for the Ditropan XL Study Group. One-year prospective, open-label trial of controlled-release oxybutynin for overactive bladder in a community-based population. Neurol Urodyn 2000;19:528–9 (Abstr)
   Google Scholar
• Appell R, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001;76:353–5
   PubMedGoogle Scholar
• Rackley R, Wein A, Nelson D. Medical treatment of overactive bladder. Mayo Clin Proc 2001;75:1179
   Google Scholar
• Gordon D, Groutz A. Evaluation of female lower urinary tract symptoms: overview and update. Curr Opin Obstet Gynecol 2001;13:521–7
   PubMed Web of Science ®Google Scholar
• Groutz A, Blaivas JG, Chaikin DC, et al. Non-invasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diaries and pad tests. J Urol 2000;164:698–701
   PubMed Web of Science ®Google Scholar
• Chapple C. Tolterodine once daily: selectivity for the bladder over effects on salivation compared to Ditropan XL. J Urol 2001;165\(No. 5 Suppl):253 (Abstract)
   Google Scholar